As second-line therapy for PsA and axSpA, no clear treatment-retention benefit at 3 years was seen when swapping to a bDMARD with another MOA.

Juvenile idiopathic arthritis, older age, and concomitant immunomodulation delay the onset of psoriasiform dermatitis in ...

Tapering TNF inhibitors is safe and maintains low disease activity for 2 years in psoriatic arthritis and axial ...

Large cohort study finds TNF inhibitors linked to lower cancer risk in psoriasis, supporting long-term safety of biologic ...

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

A growing number of women with chronic inflammatory diseases are continuing to use TNF inhibitors throughout pregnancy.

Observational data in inflammatory bowel disease (IBD) supported the safety of JAK inhibitors versus TNF inhibitors in terms of serious outcomes -- including blood clots, major heart events, and ...

However, that same analysis in JAMA Network Open found that use of TNF inhibitors was ultimately not associated with a higher risk for all-cause mortality (aHR 1.02, 95% CI 0.86-1.21).

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic ...